Clarivate Identifies Seven Innovators of New RNA Technology Company to Watch Report

Reports analyze earnings, financing, R&D activity, and more to uncover emerging talent in the medical sciences

U.S. and mainland China at the forefront of RNA technology advancements

London, October 25th February 2022 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), the global leader in delivering trusted information and insights to accelerate the pace of innovation, today announced the release of a new report, RNA Technology Companies to Watch. The report identifies seven emerging innovators in medical science who are addressing undruggable disease targets. The report draws on data and analysis from BioWorld, an award-winning suite of news services providing actionable intelligence on the most innovative treatments and medical technologies in development, published by Clarivate. Using data and insights from Clarivate and BioWorld, along with analysis of drug benefits, financing, R&D activity, and more, this report explores what sets these companies apart and why they deserve attention.

(PRNewsfoto/Clarivate Analytics)

(PRNewsfoto/Clarivate Analytics)

With great potential to address unmet therapeutic needs, therapeutics that act on or bind RNA to fight disease have gained traction over the past decade and are further garnered by the regulatory approval of mRNA vaccines during the global COVID-19 pandemic. focus on. The success of rare diseases that often respond poorly to traditional approaches sets RNA therapeutics apart. Showing benefits such as fewer side effects and lower cost to improve efficacy and accessibility, this emerging treatment modality is giving hope to patients and clinicians.

However, RNA technology presents challenges, including factors such as inherent instability limitations, high innate immunogenicity, and challenges with targeted delivery. Despite these challenges, the space remains promising. In the report, Clarivate Analytics identified seven recently created innovative RNA technology companies that are developing solutions to address non-druggable targets currently in the field, including:

  • Aro Biotherapy A pioneer in the development of tissue-targeted genetic medicines, its patented platform technology, Centyrin, is positioned to precisely target multiple therapeutics to specific cells of interest. Major projects include Centryrin-oligonucleotide conjugate therapy aimed at targeted delivery of oligonucleotides to extrahepatic tissues and Centryrin-Small Interfering (siRNA) conjugate therapy for tumor targets.

  • Cargene BiopharmaceuticalsA company developing highly specific, stable, potent, siRNA-based oligonucleotide therapeutics through the company’s OSCAR™ algorithm and SMoP™ pharmacophore design platform. The company aims to address a broad range of diseases, with an initial focus on liver and eye diseases.

  • DTx PharmaceuticalsA company that has developed a proprietary platform technology called FALCON™ (Fatty Acid Ligand Conjugated Oligonucleotides). The FALCON platform has the potential to address multiple therapeutic areas, including CNS, cardiovascular, immunology and oncology.

  • HAYA Therapeutics SAA precision therapy company developing a proprietary drug discovery engine, DiscoverHAYA™️, providing a portfolio of anti-fibrotic candidates targeting lead, long non-coding RNAs (lncRNAs) for many tissues including lung, kidney, liver and solid tumors drug microenvironment. The company’s lead development candidate (HTX-001) is an improved ASO targeting lncRNA Wisper, a fibrosis driver enriched in cardiac myofibroblasts.

  • Laronde The company’s platform, Endless RNA™ (eRNA), involves novel, closed-loop, programmable, durable, non-immunogenic RNA constructs for the expression of therapeutic proteins in vivo.

  • replicate biological sciencesA company designing self-replicating (srRNA) immunotherapies with a primary focus on drug resistance in oncology and new treatments for autoimmune and inflammatory diseases. Lead candidates include RBI-1000 for breast cancer, RBI-2000 for solid tumors, RBI-3000 for lung cancer, and RBI-8000 for inflammatory/autoimmune diseases.

  • chain therapy – An emerging company developing next-generation, programmable, long-acting mRNA therapeutics capable of delivering precise, versatile, and potentially curative single-dose treatments for cancer immunotherapy and other diseases.

Mike Ward, global head of life sciences and healthcare thought leadership at Clarivate Analytics: “The success of an mRNA vaccine against COVID-19 has drawn attention to the potential of RNA technology in the treatment of other diseases. Pharmaceutical companies are now very keen to identify the next generation of RNA-focused technologies that will deliver future medicines and potentially Possibly better medicine. Treatment.”

Lynn JoffePublisher, BioWorld says: “As RNA is known to directly regulate important cellular processes, the misregulation of various processes in disease has led to an expanding level of research, and many therapeutic strategies are now being pursued by these companies and more. BioWorld has been tracking new biopharmaceutical companies already With a history of 3 years, development time can be long. However, the speed with which mRNA technology is delivering vaccines to combat COVID-19, for example, underscores the value of this technology. These seven companies are strong examples of companies using RNA to effectively treat a variety of diseases.”

The momentum of RNA technology in recent years has been evident in the remarkable growth in scientific knowledge, intellectual property and transaction value. From 2010 to 2020, the number of patents filed globally increased by 52%, and between 2012 and 2021, the number of RNA-related research publications increased by 160%.1 also, U.S. Mainland China is at the forefront of advances in RNA technology, and activity in mainland China is accelerating.Among the top 20 organizations with RNA-related patents in the world, the patents in mainland China accounted for 41% of the total number of patents, followed by U.S. (40%).2 RNA companies need to differentiate in an increasingly crowded market by identifying target markets that promote long-term viability and ultimately maximize patient benefit and commercial success.

To learn more about the RNA Technologies Inc. Watch report, please visit here.

For more noteworthy drug updates and analysis throughout the year, visit Drug Watch Page And follow Clarivate’s life sciences and healthcare Twitter and LinkedIn.

RNA Technologies Inc. observes the reporting method

Clarivate analysts assess the changing RNA landscape using a variety of proprietary data sources, including: Bioworld™, Cortellis Transaction Intelligence™, Derwent Innovations™, Web of Science™ and other industry sources such as company announcements, documents, and peer-reviewed publications. Clarivate experts and analysts weight companies based on factors including: the medical, commercial and scientific challenges these companies are trying to solve; the unmet needs of patients and/or the disease burden their solutions are designed to address; whether the company has demonstrated concepts and achieved key development milestones; clinical trial positioning; relationships with prominent scientific and academic institutions; financial status, including funding security, relationships with industry and institutional investors, financial status, and prospects for future fundraising or collaboration; Ownership and status of intellectual property (IP) property.

Please note that data generated by Clarivate Analytics in this report reflects previous findings October 21, 2022Notable RNA technology companies are based on Clarivate’s current expectations of existing data, but actual results from companies named in the report and in this article may vary.

About Bioworld

Published by Clarivate, BioWorld features writers and editors around the world, covering breaking news and providing insights into hundreds of therapies and devices in development, the companies behind these drug candidates, the business development deals that are driving the market, and challenges and protections Regulatory barriers to the process. BioWorld has a long tradition of excellence in journalism. Since 1998, these news services have won a total of 63 awards, 15 of which are for their daily news service.

Join the conversation and mention BioWorld Twitter and Clarivate Life Sciences & Healthcare Twitter and LinkedIn.

About Clarivate Analytics

Clarivate™ is a global leader in providing solutions to accelerate the pace of innovation. Our bold mission is to help clients solve some of the world’s most complex problems by providing actionable information and insights to reduce the transition from new ideas to life-changing in academia and government, life sciences and healthcare, professional services and consumers. Invented time goods, manufacturing and technology. We use our trusted subscription and technology-based solutions and deep domain expertise to help clients discover, protect and commercialize their inventions. For more information, visit

1 Source: Web of Science™
2 Source: Derwent Innovations

Media Contact:
Katherine Daniel
Director of External Communications, Life Sciences and Healthcare



View original content to download multimedia:

Source Clarivate Analytics

Source link